F-star Therapeutics, Inc. Common Stock
FSTX
FSTX was delisted on the 8th of March, 2023.
50 hedge funds and large institutions have $25M invested in F-star Therapeutics, Inc. Common Stock in 2019 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 16 increasing their positions, 10 reducing their positions, and 14 closing their positions.
60% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 10
1.71% less ownership
Funds ownership: 42.93% → 41.22% (-1.7%)
7% less funds holding
Funds holding: 54 → 50 (-4)
14% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 14
66% less capital invested
Capital invested by funds: $74M → $25M (-$49M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$2.85M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
+$2.34M |
| 3 |
Millennium Management
New York
|
+$1.43M |
| 4 |
Goldman Sachs
New York
|
+$660K |
| 5 |
Renaissance Technologies
New York
|
+$631K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
-$5.55M |
| 2 |
BlackRock
New York
|
-$3.22M |
| 3 |
State Street
Boston,
Massachusetts
|
-$1.19M |
| 4 |
MAM
Morse Asset Management
Darien,
Connecticut
|
-$918K |
| 5 |
CWG
C WorldWide Group
Copenhagen,
Denmark
|
-$547K |
FSTX Hedge Fund Activity: Q2 2019 in Review
50 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in F-star Therapeutics, Inc. Common Stock (FSTX) for Q2 2019, worth a combined $25M — down 66% from $74M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of FSTX and 12 opened new positions — a net loss of 2 holders — while 10 trimmed existing stakes and 16 added.
The largest buyer was Adage Capital Partners, adding an estimated $2.85M. The largest seller was Jennison Associates, exiting entirely with an estimated $5.55M sold.
- 50 institutional investors held F-star Therapeutics, Inc. Common Stock (FSTX) as of Q2 2019, down from 54 in Q1 2019.
- Funds reported $25M of F-star Therapeutics, Inc. Common Stock stock for Q2 2019, down 66% quarter-over-quarter.
- 12 funds opened new F-star Therapeutics, Inc. Common Stock positions in Q2 2019 and 14 closed out, a net change of -2 holders.
- The largest F-star Therapeutics, Inc. Common Stock buyer in Q2 2019 was Adage Capital Partners, an estimated $2.85M added.
- The largest F-star Therapeutics, Inc. Common Stock seller in Q2 2019 was Jennison Associates, an estimated $5.55M sold.
Based on aggregated 13F filings for Q2 2019.